



SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network

Silke van Koningsbruggen-Rietschel¹, Fiona Dunlevy², Veerle Bulteel², Damian G. Downey³ and Lieven Dupont⁴

Affiliations: ¹CF Centre Cologne, Children's Hospital, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. ²European Cystic Fibrosis Society, Karup, Denmark. ³Centre for Experimental Medicine, Queen's University Belfast, Belfast, UK. ⁴CF Center and Lung Transplant Unit, University Hospitals Leuven, Leuven, Belgium.

Correspondence: Silke van Koningsbruggen-Rietschel, Children's Hospital, University of Cologne, CF Center Cologne, Kerpenerstr. 62, Cologne 50924, Germany. E-mail: Silke.vanKoningsbruggen@uk-koeln.de



@ERSpublications

Rare disease patients may suffer delayed access to new drugs as SARS-CoV-2 is disrupting clinical trials. This survey demonstrates that the European Cystic Fibrosis Clinical Trials Network is ideally placed to track and address such disruption. <https://bit.ly/3hCw5dq>

Cite this article as: van Koningsbruggen-Rietschel S, Dunlevy F, Bulteel V, *et al.* SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network. *Eur Respir J* 2020; 56: 2002114 [<https://doi.org/10.1183/13993003.02114-2020>].

This single-page version can be shared freely online.

To the Editor:

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has disrupted clinical trials worldwide [1]. This could delay the approval of new medicines and reduce access to investigational treatments *via* clinical trials. This particularly impacts patients with rare diseases such as cystic fibrosis (CF).